Purpose: PET studies with >[C-11]methyl-L-tryptophan (AMT) have shown decreased serotonin synthesis based on a decrease of the unidirectional uptake rate (K-complex) in neuropsychiatric conditions such as autism and depression. Increased AMT K-complex in tumors can indicate increased tryptophan metabolism via the immunosuppressive kynurenine pathway. Moreover, apparent AMT volume of distribution (VD ¶) reflects net tryptophan transport from blood to tissue. We evaluated if kinetic parameters (K-complex, VD ¶) of AMT, measured by PET, can predict the proliferative activity of glioma, and if these AMT parameters are altered in the remote cortex. Methods: We evaluated dynamic AMT PET images of 30 adult patients with grade 2 to 4 gliomas according to the World Health Organization's classification to determine tumoral AMT VD ¶ and K-complex values, which were correlated with tumor proliferative activity as assessed by the Ki-67 labeling index in resected tumor specimens. We also compared cortical VD ¶ and K-complex values between patients with glioma and healthy controls. Results: Both VD ¶ and K-complex values were significantly higher in gliomas than in the contralateral cortex (VD ¶, P G 0.001; K-complex, P G 0.001). Tumoral VD ¶ values and tumor/cortex VD ¶ ratios, but not the K-complex, showed strong positive correlations with the proliferative activity of glioma (P e 0.001). The contralateral frontal cortex showed decreased AMT VD ¶ and K-complex in patients with glioma compared with those in controls (P e 0.01). Conclusions: Increased net amino acid transport into tumor tissue, quantified by PET, can serve as an imaging marker of the proliferative activity of glioma. The data also suggest a glioma-induced down-regulation of cortical serotonin synthesis, likely mediated by shunting of tryptophan from serotonin synthesis to kynurenine metabolism.
P
roliferative activity in gliomas, as measured by nuclear labeling of the Ki-67 antigen in surgical specimens, has important prognostic significance. 1 Because this marker cannot practically be measured serially, various neuroimaging techniques have been studied for their ability to noninvasively assess the proliferative activity of glioma. Among MRI techniques, proton magnetic resonance spectroscopy shows promise as a surrogate marker of glioma proliferation. 2 PETusing FDG is a poor predictor of the proliferative activity of glioma. 3 However, tumoral uptake of some other PET tracers (eg, 3Y7 Some have also suggested that kinetic analysis of PET images may provide a more accurate measure of the proliferative activity of glioma than radiotracer uptake alone. 4, 5 >[C-11]methyl-L-tryptophan (AMT) is an amino acid PET radiotracer that is not incorporated into proteins. AMT PET provides a noninvasive method of imaging tryptophan metabolism into serotonin in the brain. 8, 9 Focal cortical decrease of the unidirectional AMTuptake rate (K-complex), a measure of AMT trapping related to serotonin synthesis, has been observed in children with autism 10 and a variety of other neuropsychiatric disorders, including depression, 11Y13 which is also a common comorbidity in patients with glioma. 14 In addition to measuring brain serotonin synthesis, AMT PET can also estimate tryptophan metabolism via the kynurenine pathway under certain conditions. 15 The significance of this pathway is negligible in normal brain, but increased tryptophan metabolism via this pathway can occur in cancers, where it contributes to tumoral immunoresistance. 16 Increased expression and activity of indoleamine 2,3-dioxygenase (IDO), the initial and rate-limiting enzyme of the kynurenine pathway, was reported in human gliomas. 17, 18 Increased IDO activity may play a role in accumulation of AMT in both low-grade and high-grade gliomas. 18, 19 Increased tumoral AMT accumulation can be also the result of increased AMT volume of distribution (VD), which measures the ratio of radioligand concentration in the tissue to that in the plasma at equilibrium; this ratio will increase as a result of an increased net transport of the radiotracer from plasma to tissue. Consistent with this, high apparent VD values (ie, VD ¶) were found in gliomas with gadolinium enhancement (indicating impaired blood-brain barrier) and also in brain tumors showing a high expression of the L-type amino acid transporter (LAT1), which is commonly upregulated in brain tumors. 20, 21 In this study, we assessed the ability of dynamic AMT PET imaging to predict the proliferative activity of gliomas in vivo. We hypothesized that a positive correlation exists between the Ki-67 labeling index measured in surgically resected gliomas and AMT VD ¶ measured by PET. In addition, because up-regulation of the kynurenine pathway in patients with malignant tumors may lead to systemic changes in tryptophan metabolism via the serotonin pathway, 22, 23 we also tested whether patients with gliomas have decreased unidirectional uptake rates of AMT, indicating reduced serotonin synthesis, in cortical areas remote from the tumor.
SUBJECTS AND METHODS

Subjects
Thirty patients, 20 men and 10 women, with a mean age of 48 years (range, 21Y68 y; Table 1 ) were included in the study based on the following inclusion criteria: (1) aged 18 years or older, (2) presence of a solid supratentorial brain tumor on MRI, (3) no prior treatment (including surgery, radiation, or chemotherapy) before AMT PET, (4) microsurgical resection of tumor with a diagnosis of grade 2 to 4 glioma according to the World Health Organization's classification (WHO) on histopathologic examination, and (5) a body mass index of 20 kg/m 2 or higher. Mean time between AMT PET imaging and subsequent tumor resection was 23 days (range, 1Y105 days). All 10 glioblastomas were resected within 2 weeks after PET. The only tumor where more than 2 months elapsed between PET and surgery was a grade 2 oligodendroglioma that showed no MRI changes between the time of PET and surgery. In addition, we selected the 7 oldest healthy control subjects (3 women and 4 men) from our AMT PET database (mean age, 33 y; range, 25Y48 y). All control subjects were older than 21 years, did not have a history of neurological or neuropsychiatric disorder, and were not taking any medication. All subjects underwent dynamic AMT PET scanning using the same protocol (see next paragraphs). The study was approved by Wayne State University's Institutional Review Board, and written informed consent was obtained from all participants.
AMT PET Scanning Protocol
All AMT PET studies were performed using the Siemens EXACT/HR whole-body positron tomograph (Knoxville, Tenn) located at the PET Center of the Children's Hospital of Michigan in Detroit, using a research protocol as described previously. 19, 24 In brief, after 6 hours of fasting, AMT (0.1 mCi/kg) was injected through a venous line. A second venous line was established for collection of timed blood samples. A 20-minute dynamic PET scan of the heart was performed in 2D mode to obtain the blood input function (concentration of radioactivity in blood) from the left ventricle of the heart. Determination of the blood input function beyond this time was accomplished by direct measurement of radioactivity in serial venous blood samples (0.5 mL/sample, collected at 20, 30, 40, 50, and 60 minutes after AMT injection). At 25 minutes after tracer injection, a dynamic emission scan of the brain (7 Â 5 minutes) was started. Measured attenuation correction using a rotating Ge-68 rod source was applied to the AMT PET images of the heart, whereas computed attenuation correction was used to correct the brain images.
AMT PET Image Analysis
Regions of interest (ROIs) were drawn on AMT summed uptake images from 30 to 55 minutes after tracer injection (Fig. 1) . In tumor patients, ROIs included the tumor mass, excluding apparently necrotic portions (if present) visualized on coregistered MRI scans, using the ROI Editor 1.4.1 software (www.mristudio.org). Regions of interest of similar size were also drawn in the contralateral homotopic cortex. In addition, ROIs encompassing the middle frontal gyrus region of the frontal cortex were drawn on summed AMT PET images of both study patients (contralateral to the tumor) and healthy controls (both sides). All ROIs were then applied to the dynamic AMT PET image sequence. Thereafter, kinetic AMT parameters were calculated using the blood input function entered in the Patlak graphical analysis 25 for both the tumor mass and cortical regions, as described previously. 18, 19, 24 This approach provides 2 kinetic parameters: (1) the y intercept of the Patlak plot yields the tracer's apparent volume of distribution (VD ¶), which is tightly correlated with VD values derived from compartmental analysis [VD = K 1 / (k 2 + k 3 ), where K 1 (mL/g per minute) represents the forward and k 2 (per minute) represents the reverse combined transport of AMT across the blood vessel, interstitial space, and cell membrane into the cytoplasm, whereas k 3 (per minute) represents the metabolic rate constant that reflects tracer accumulation in the metabolic (irreversible) compartment (in case of tryptophan metabolism via the serotonin and/or kynurenine pathways)], 26 therefore AMT VD ¶ values are indicative of the net transport of tryptophan into the tissue of interest (tumor or cortex); and (2) the slope of the Patlak plot, which reflects the unidirectional uptake of tracer into the tissue (Kcomplex) and correlates with tryptophan metabolism via the serotonin synthesis pathway in the cortex. 9, 15 In brain tumors, with no evidence of serotonin synthesis, the most likely mechanism of an increase in AMT K-complex is tryptophan metabolism via the kynurenine pathway. 15 The advantages and limitations of using these kinetic AMT PET parameters have been discussed previously.
9,24
Histopathology and Evaluation of Ki-67 Labeling Index in Resected Gliomas
Standard neuropathologic examination of all tumor specimens was performed by an experienced board-certified neuropathologist (W.J.K.). Immunohistochemical staining for Ki-67 (CONFIRM antiKi-67 rabbit monoclonal antibody, clone 30-9; Ventana Medical Systems, Inc, Tucson, Ariz) was performed to assess tumor proliferative activity. The Ki-67 labeling index was determined by identifying the areas of greatest tumor cellularity, examining at least 10 fields at 400Â (highpower) magnification on an Olympus microscope (Olympus Inc, Center Valley, PA), and determining the ratio between the number of Ki67Ypositive tumor cell nuclei and the total number of tumor cell nuclei in each high-power field (Fig. 1) . The proliferation index was expressed as a percent range (lowest to highest) in the 10 high-power fields (eg, 5%Y10%). Small, isolated fields with higher Ki-67 labeling, which were not reflective of the entire tumor mass, were excluded from the analysis. The middle value of the defined range was then used in correlations with the PET variables.
Study Design and Statistical Analysis
An abnormal increase of tumoral VD ¶ or K-complex was defined as a value more than 10% higher than the corresponding value in the contralateral homotopic cortex (ie, tumor/cortex ratio 91.10). 19 For statistical analysis, nonparametric tests were used because several variables showed nonnormal distribution. First, tumoral and contralateral cortical VD ¶ and K-complex values were compared in the patient group using the Wilcoxon signed rank test. Then, tumoral VD ¶ and K-complex values as well as tumor/contralateral homotopic cortex VD ¶ and K-complex ratios were entered in Spearman rank correlations with corresponding tumor Ki-67 labeling index (%) values. Next, frontal cortical VD ¶ and K-complex values were compared between patients with glioma and healthy controls (where the average of the left and right values were used) using the Mann-Whitney U test. This comparison was repeated: (i) in a subgroup of younger patients (age e50 y, n = 15), whose age was closer to that of the controls (36 vs 33 y, P = 0.49); (ii) in a subgroup of patients who were not treated with dexamethasone before AMT PET scanning (n = 22), to exclude potential confounding effects of steroids on imaging findings caused by decreased blood-brain barrier permeability and altered tumoral perfusion 27 ; and (iii) in a subgroup that included only younger (age e50 y) steroid-free patients (n = 10). Finally, cortical AMT PET kinetic parameters were compared between patients with a high Ki-67 labeling index (midrange value of Ki-67 9 10%, n = 12) and a low Ki-67 labeling index (e10%, n = 18) using the Mann-Whitney U test. Statistical analysis was carried out using the SPSS Statistics 19.0 software (SPSS, Inc, Somers, NY). P G 0.05 was considered to be significant.
RESULTS
AMT PET Kinetic Parameters in Gliomas: Correlation With Ki-67 Labeling Index
Of the 30 tumors analyzed, 28 (all except 1 grade 2 oligodendroglioma and 1 grade 2 oligoastrocytoma) showed increased VD ¶ and 24 tumors demonstrated increased AMT K-complex (Table 1) Table 1 ) with a right temporal lobe glioblastoma. Ki-67 immunostaining (C) in the resected tumor (original magnification, Â400) shows strong Ki-67Ypositive nuclei in 10% to 15% of the cells.
AMT Accumulation in Cortex: Comparison Between Patients With Glioma and Healthy Controls
Contralateral frontal cortical AMT VD ¶ and K-complex values were both lower in the group with glioma than in the healthy control group [VD ¶, 0.28 (0.08) vs 0.41 (0.1), respectively, P = 0.01; Kcomplex, 0.0044 (0.001) vs 0.0056 (0.001), respectively, P = 0.009]. These group differences remained significant for K-complex values but showed a variable degree of significance for VD ¶ values in the studied subgroups: (i) patients 50 years and younger (K-complex, P = 0.014; VD ¶, P = 0.07), (ii) the subgroup of patients without steroid treatment before AMT PET (K-complex, P = 0.012; VD ¶, P = 0.03), and (iii) the smallest subgroup that included only younger (e50 years), steroid-free patients (K-complex P = 0.04; VD ¶ P = 0.11).
AMT PET Kinetic Parameters in the Cortex: Effect of the Proliferative Activity of Glioma 
DISCUSSION
Whereas most malignant gliomas demonstrate increased AMT VD ¶ and unidirectional uptake on PET compared with contralateral homotopic cortex, our data indicate that the tumor AMT VD ¶ (a kinetic PET imaging parameter related to net transport of tryptophan from blood into tissue) and tumor/cortex VD ¶ ratio are good imaging predictors of tumor proliferative activity in WHO grade 2 to 4 gliomas. In addition, decreased AMT K-complex values in the frontal cortex contralateral to the tumor indicate impaired serotonin synthesis in nontumoral cortex in these patients compared with healthy controls. This may be the result of a systemic tumor effect on tryptophan metabolism, possibly mediated by an up-regulation of the kynurenine pathway leading to decreased availability of tryptophan for serotonin synthesis in extratumoral tissues.
Increased tryptophan transport into the tumor mass may be explained by several mechanisms, including (i) increased diffusion across an impaired blood-brain barrier, (ii) increased expression and activity of the tryptophan carrier L-type amino acid transporter, 20, 28 and/or (iii) increased tumoral microvasculature that can facilitate dissociation of tryptophan from albumin. 29 Consistent with this, in our previous studies with AMT PET in various brain tumors, we have found that contrast-enhancing gliomas showed higher VD ¶ values than nonenhancing tumors, 24 and we have also found high VD ¶ values in nonenhancing grade 1 dysembryoplastic neuroepithelial tumors, which showed high expression of the L-type amino acid transporter at the blood-brain-barrier. 21 These data support the notion that high VD ¶ values can be related to a combination of blood-brain barrier impairment, increased tumor vascularity, and high expression of the transporter, all of which can result in higher net tracer transport into tumor tissue in gliomas with high proliferative activity.
Increased amino acid influx into malignant gliomas provides more building blocks for cellular protein synthesis. Tryptophan transported from blood into tumor tissue is also a substrate for IDO. Gliomas can express IDO both constitutively 17 and after the release of cytokines (especially interferon-F) in the tumor microenvironment. 30, 31 Increased tumoral IDO activity causes much more tryptophan metabolism via the kynurenine pathway than the serotonin pathway, which could lead to tryptophan shortage and accumulation of toxic kynurenine metabolites; both of these promote tumoral immune tolerance. 16, 30 Unlike AMT transport, tumoral accumulation of AMT (as measured by tumoral K-complex values) does not seem to be tightly correlated with tumoral proliferative activity. This may be explained by our previous observation demonstrating increased expression of IDO in gliomas with various histologic grades. 18 Decreased tryptophan accumulation in cerebral cortex contralateral to the tumor in patients with glioma compared with healthy controls has not been previously reported and deserves further investigation. Cortical AMT K-complex is a macroparameter that estimates brain serotonin synthesis. 8, 9 Decreased contralateral frontal K-complex values in patients with glioma, therefore, may suggest an overall reduction in cortical serotonergic activity. This decreased activity might be caused by a systemic effect from activation of IDO and the kynurenine pathway in tumor cells. In keeping with this theory, patients with extracranial malignancies (eg, lung and ovarian cancer) have decreased levels of tryptophan and elevated levels of kynurenine in the blood. 22, 23 Our results suggest that a similar mechanism may be operative in malignant gliomas, where tumoral IDO activation results in decreased systemic tryptophan availability. Whether this is indeed the case in patients with glioma, and whether such systemic tryptophan changes play a role in altered cortical tryptophan metabolism, remains to be determined. PET studies of serotonin synthesis suggested that severe, acute tryptophan depletion can lead to reductions of brain serotonin synthesis. 32 However, the AMT K-complex is a relatively stable macroparameter with a relative independence of actual plasma tryptophan levels (an issue that has been discussed in detail by Chugani and Muzik 15 ). It remains to be determined how long-term reductions of blood tryptophan levels, with associated increases in kynurenine metabolites, often seen in cancer patients, can account for a reduction of serotonin biosynthesis in the central nervous system. The observed decreases of AMT K-complex values may be also explained by a long-term systemic shift between serotonin and kynurenine metabolism of tryptophan, with a net result of lower tryptophan metabolism in the cortex.
Decreased cortical serotonergic function, suggested by lower AMT K-complex values measured by PET, may have important implications for neuropsychiatric comorbidities in patients with glioma. Decreased cortical AMT K-complex values have been reported in previous PET studies of patients with various psychiatric conditions, such as borderline personality disorder, 11 alcoholism, 13 and major depression. 12 Depression is a common and often unrecognized condition in patients with infiltrating gliomas. 14,33 A population-based study found depression in about one third of patients with primary brain tumors, with similar severity across various tumor types and locations. 34 The ''serotonin hypothesis'' may explain the presence of depression in patients with glioma. This hypothesis postulates that depression is caused by a depletion of serotonin, which may be caused by immune-mediated shunting of tryptophan from serotonin to kynurenine synthesis. 35Y39 There are several lines of evidence suggesting that this mechanism may play a central role in cancer-associated depression. 40 However, further studies are needed to determine the precise role of the accumulation of toxic kynurenine metabolites and concomitant serotonergic abnormalities in the central nervous system, including several other cortical regions, in the development of depression associated with human gliomas.
Although we focused on assessing the Ki-67 labeling of tumor areas with the greatest cellularity, we did not do stereotactic matching of histology and imaging in this study. It is likely that the correlation between tumoral AMT uptake and Ki-67 labeling would be even stronger if the location of tissue sampling were matched accurately with the AMT PET abnormality by image-guided biopsy. 7 This approach could also address the contribution of other potential factors, such as glioma microvessel density, to in vivo tracer transport. Nevertheless, the present data provide evidence that the net blood-totumor transport of AMT (and, potentially, other PET radiotracers with similar transport mechanisms) could be a useful imaging marker of proliferative activity in malignant gliomas.
